You are totally right Southern
Dose escalation in small cohorts to find optimum therapeutic dose is a basic requirement.
AIPAC (01) phase 2b at 30mg missed by such a small margin that it is almost a given, had 90mg been the approved dose, Efti would be approved today.
Essentially, Immutep lost several years and $ millions to realise such a fundamental dose escalation protocol.
Very disappointed ex long standing shareholder
EFTI at 90, page-5
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
-0.005(1.23%) |
Mkt cap ! $584.6M | |||
| Open | High | Low | Value | Volume |
| 40.5¢ | 40.5¢ | 39.5¢ | $998.2K | 2.495M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7607 | 39.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 36888 | 3 |
View Market Depth
| Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
| IMM (ASX) Chart |